-+ 0.00%
-+ 0.00%
-+ 0.00%

We're Interested To See How Prelude Therapeutics (NASDAQ:PRLD) Uses Its Cash Hoard To Grow

Simply Wall St·11/18/2026 10:16:07
Listen to the news

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.

Given this risk, we thought we'd take a look at whether Prelude Therapeutics (NASDAQ:PRLD) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). Let's start with an examination of the business' cash, relative to its cash burn.

When Might Prelude Therapeutics Run Out Of Money?

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at September 2026, Prelude Therapeutics had cash of US$140m and no debt. In the last year, its cash burn was US$28m. Therefore, from September 2026 it had 5.0 years of cash runway. Importantly, though, analysts think that Prelude Therapeutics will reach cashflow breakeven before then. In that case, it may never reach the end of its cash runway. Depicted below, you can see how its cash holdings have changed over time.

debt-equity-history-analysis
NasdaqGS:PRLD Debt to Equity History November 18th 2026

Check out our latest analysis for Prelude Therapeutics

How Well Is Prelude Therapeutics Growing?

Prelude Therapeutics managed to reduce its cash burn by 72% over the last twelve months, which suggests it's on the right flight path. Arguably, however, the revenue growth of 105% during the period was even more impressive. Overall, we'd say its growth is rather impressive. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Easily Can Prelude Therapeutics Raise Cash?

While Prelude Therapeutics seems to be in a decent position, we reckon it is still worth thinking about how easily it could raise more cash, if that proved desirable. Companies can raise capital through either debt or equity. Commonly, a business will sell new shares in itself to raise cash and drive growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

Prelude Therapeutics' cash burn of US$28m is about 8.1% of its US$345m market capitalisation. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.

So, Should We Worry About Prelude Therapeutics' Cash Burn?

As you can probably tell by now, we're not too worried about Prelude Therapeutics' cash burn. For example, we think its revenue growth suggests that the company is on a good path. And even its cash burn relative to its market cap was very encouraging. One real positive is that analysts are forecasting that the company will reach breakeven. After considering a range of factors in this article, we're pretty relaxed about its cash burn, since the company seems to be in a good position to continue to fund its growth. Its important for readers to be cognizant of the risks that can affect the company's operations, and we've picked out 1 warning sign for Prelude Therapeutics that investors should know when investing in the stock.

Of course Prelude Therapeutics may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.